Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2021 Dec 16;385(25):2313-2324.
doi: 10.1056/NEJMoa2113380. Epub 2021 Nov 5.

Daprodustat for the Treatment of Anemia in Patients Not Undergoing Dialysis

Ajay K Singh  1 , Kevin Carroll  1 , John J V McMurray  1 , Scott Solomon  1 , Vivekanand Jha  1 , Kirsten L Johansen  1 , Renato D Lopes  1 , Iain C Macdougall  1 , Gregorio T Obrador  1 , Sushrut S Waikar  1 , Christoph Wanner  1 , David C Wheeler  1 , Andrzej Więcek  1 , Allison Blackorby  1 , Borut Cizman  1 , Alexander R Cobitz  1 , Rich Davies  1 , Tara L DiMino  1 , Lata Kler  1 , Amy M Meadowcroft  1 , Lin Taft  1 , Vlado Perkovic  1 ; ASCEND-ND Study Group
Collaborators, Affiliations
Free article
Clinical Trial

Daprodustat for the Treatment of Anemia in Patients Not Undergoing Dialysis

Ajay K Singh et al. N Engl J Med. .
Free article

Abstract

Background: Daprodustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor. In patients with chronic kidney disease (CKD) who are not undergoing dialysis, the efficacy and safety of daprodustat, as compared with the conventional erythropoiesis-stimulating agent darbepoetin alfa, are unknown.

Methods: In this randomized, open-label, phase 3 trial with blinded adjudication of cardiovascular outcomes, we compared daprodustat with darbepoetin alfa for the treatment of anemia in patients with CKD who were not undergoing dialysis. The primary outcomes were the mean change in the hemoglobin level from baseline to weeks 28 through 52 and the first occurrence of a major adverse cardiovascular event (MACE; a composite of death from any cause, nonfatal myocardial infarction, or nonfatal stroke).

Results: Overall, 3872 patients were randomly assigned to receive daprodustat or darbepoetin alfa. The mean (±SD) baseline hemoglobin levels were similar in the two groups. The mean (±SE) change in the hemoglobin level from baseline to weeks 28 through 52 was 0.74±0.02 g per deciliter in the daprodustat group and 0.66±0.02 g per deciliter in the darbepoetin alfa group (difference, 0.08 g per deciliter; 95% confidence interval [CI], 0.03 to 0.13), which met the prespecified noninferiority margin of -0.75 g per deciliter. During a median follow-up of 1.9 years, a first MACE occurred in 378 of 1937 patients (19.5%) in the daprodustat group and in 371 of 1935 patients (19.2%) in the darbepoetin alfa group (hazard ratio, 1.03; 95% CI, 0.89 to 1.19), which met the prespecified noninferiority margin of 1.25. The percentages of patients with adverse events were similar in the two groups.

Conclusions: Among patients with CKD and anemia who were not undergoing dialysis, daprodustat was noninferior to darbepoetin alfa with respect to the change in the hemoglobin level from baseline and with respect to cardiovascular outcomes. (Funded by GlaxoSmithKline; ASCEND-ND ClinicalTrials.gov number, NCT02876835.).

PubMed Disclaimer

Comment in

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

Publication types

MeSH terms

Associated data

Grants and funding